← Back to Portfolio

Sierra Oncology

Sierra Oncology is a biopharmaceutical company focussing on the treatment of Myelofibrosis. The company's lead product Momelotinib (a JAK1, JAK2 & ACVR1 inhibitor) is in a phase 3 clinical study in second line Myelofibrosis patients. The drug was previously licensed to Gilead and has been in over 820 patients. Sierra is listed on the Nasdaq with ticker: SRRA

LocationVancouver, Canada
CEONick Glover
Partner Andrew Sinclair
Websitewww.sierraoncology.com